Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,933 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lipid Disorder Clear all
Completed No phase listed Observational

Effects of Enzyme Replacement in Gaucher's Disease

NCT00001289
View directory record Official record
Conditions
Gaucher's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 3:55 PM EDT
Completed No phase listed Observational Results available

Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey

NCT04317690
View directory record Official record
Conditions
High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

NCT00585143
View directory record Official record
Conditions
Dyslipidemia, Renal Insufficiency
Interventions
ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 4 Interventional

Fluvastatin in Adults With Dislipidemia With History of Muscle Problems

NCT00125125
View directory record Official record
Conditions
Dyslipidemia
Interventions
Fluvastatin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
12 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Tampa, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 3:55 PM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Extension Study of PRX-102 for up to 60 Months

NCT01981720
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa)
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Not applicable Interventional

Oil Consumption and Cholesterol

NCT04397055
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Cottonseed Oil, Olive Oil
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
30 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

NCT01443650
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab SAR236553 (REGN727)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 23, 2026, 3:55 PM EDT
Not listed Phase 2 Interventional

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

NCT00299897
View directory record Official record
Conditions
HIV Infections, Human Immunodeficiency Virus
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2006 · Synced Oct 23, 2026, 3:55 PM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

NCT03566017
View directory record Official record
Conditions
Fabry Disease
Interventions
pegunigalsidase alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

NCT04516291
View directory record Official record
Conditions
Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Interventions
Vupanorsen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
59
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoolSculpting and EMS for the Abdomen

NCT03738891
View directory record Official record
Conditions
Body Fat Disorder
Interventions
Zeltiq CoolSculpting System alone, Electromagnetic Muscle Stimulation alone, EMS followed by CoolSculping, CoolSculpting followed by EMS
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
22 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Marina del Rey, California • Pleasanton, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

NCT04270682
View directory record Official record
Conditions
CTX
Interventions
Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Month and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Aurora, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators

NCT01610661
View directory record Official record
Conditions
Dyslipidemia
Interventions
Diet
Other
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 23, 2026, 3:55 PM EDT
Completed No phase listed Observational Results available

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

NCT02638220
View directory record Official record
Conditions
Cerebrotendinous Xanthomatosis (CTX)
Interventions
Not listed
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
44
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

NCT01161082
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
REGN727(SAR236553)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 23, 2026, 3:55 PM EDT
Recruiting No phase listed Observational

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

NCT03087253
View directory record Official record
Conditions
Lipodystrophy (Genetic or Acquired, Non HIV)
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 4 Interventional

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

NCT00222833
View directory record Official record
Conditions
Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions
Aripiprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 23, 2026, 3:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Scans in Normal Volunteers and Patients With Fabry Disease

NCT00005111
View directory record Official record
Conditions
Fabry Disease, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 23, 2026, 3:55 PM EDT